Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Current Drug Targets|January 7, 2014
MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistanceGiuseppe Barone, Deborah A Tweddle, Jason M Shohet, et al.
Oncotarget|May 15, 2018
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastomaSaurabh Agarwal, Giorgio Milazzo, Kimal Rajapakshe, et al.
Oncotarget|July 26, 2018
Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastomaSaurabh Agarwal, Giorgio Milazzo, Kimal Rajapakshe, et al.
Cancer Research|February 28, 2002
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastomaJason M Shohet, M John Hicks, Sharon E Plon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 18, 2009
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expressionNabil Ahmed, Vita S Salsman, Eric Yvon, et al.
Plos One|February 7, 2015
WIP1 phosphatase as a potential therapeutic target in neuroblastomaMark Richter, Tajhal Dayaram, Aidan G Gilmartin, et al.
Journal of Pediatric Surgery|June 20, 2016
The optimal timing of surgical resection in high-risk neuroblastomaYesenia Rojas, Sergio Jaramillo, Karen Lyons, et al.
Plos One|December 19, 2013
A p53 drug response signature identifies prognostic genes in high-risk neuroblastomaEveline Barbieri, Katleen De Preter, Mario Capasso, et al.
Pageof 8